Immune Checkpoint Inhibitor Combination Therapy versus Sunitinib as First-Line Treatment for Favorable-IMDC-Risk Advanced Renal Cell Carcinoma Patients: A Meta-Analysis of Randomized Clinical Trials.
- Resource Type
- Article
- Source
- Biomedicines; Mar2022, Vol. 10 Issue 3, p577, 15p
- Subject
IMMUNE checkpoint inhibitors SUNITINIB CLINICAL trials RENAL cell carcinoma SORAFENIB PEMBROLIZUMAB PROGRESSION-free survival - Language
- ISSN
- 22279059